Clinical Implication of XXXX @entity32278 Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma @entity1 : A Case Control Study.

@entity1 @entity1149 @entity72246 @entity4179 @entity32278
BACKGROUND: The @entity4179 ( @entity4179 ) plays important roles in @entity1149 ( @entity1149 ) susceptibility and functional polymorphism in the @entity4179 ( @entity72246 ) gene has been linked to increased risk of @entity1149 . This study aimed to evaluate the role of the @entity4179 @entity72246 polymorphism in risk of @entity1149 (ADC) occurrence and survival in an Indian population. MATERIALS AND METHODS: This case- control study included 100 histopathologically confirmed @entity1149 (ADC) @entity1 and 100 healthy controls. @entity4179 ( @entity32278 ) was genotyped by AS-PCR to elucidate putative associations with clinical outcomes. The association of the polymorphism with the survival of @entity1149 @entity1 was estimated by Kaplan-Meier curves. RESULTS: It was found that @entity4179 61AG heterozygous and GG homozygous genotype is significantly associated with increased risk of @entity1149 (ADC) occurrence compared to AA genotype, [OR 2.61 (1.31-5.18) and 3.25 (1.31-8.06), RR 1.51(1.15-2.0) and 1.72 (1.08-2.73) and RD 23.2 (6.90-39.5) and 28.53(7.0-50.1) for heterozygous AG (p=0.005) and homozygous GG (p=0.009)]. @entity1 homozygous for the G allele exhibited a significantly poor overall survival. The median survival time for @entity1 with @entity4179 61 AA, AG, and GG genotypes was 10.5, 7.4, and 7.1 months (p=0.02), respectively. @entity1149 (ADC) @entity1 with GG + AG exhibited 7.3 months median survival compared to the AA genotype (p=0.009). CONCLUSIONS: The present study revealed that the @entity4179 @entity32278 genotype may be a novel independent prognostic marker to identify @entity1 at higher risk of occurrence and an unfavourable clinical outcome.
